Lefamulin

Drug Profile

Lefamulin

Alternative Names: BC-3781

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Nabriva Therapeutics
  • Class Alkenes; Antibacterials; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
  • Mechanism of Action Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia
  • Phase II Skin and soft tissue infections
  • Preclinical Bone and joint infections; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections

Most Recent Events

  • 16 Nov 2016 Nabriva announces intention to submit NDA to the US FDA and MAA to EMA in 2018
  • 31 Oct 2016 Pharmacokinetics data from phase I trials in Community-acquired pneumonia released by Nabriva
  • 20 Jun 2016 Antimicrobial data from in-vitro studies in Community-acquired pneumonia released by Nabriva Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top